About Readline
Readline is a company based in Shenzhen (China) founded in 2013 by Jian Liu. Readline has raised $143.22 million across 3 funding rounds from investors including Gree, Jinhong Holding Group and Oriental Fortune Capital. Readline offers products and services including Efficacy Care Raw Materials and Biomedicine Peptides.
- Headquarter Shenzhen, China
- Founders Jian Liu
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name 深圳瑞德林生物技术有限公司
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$143.22 M (USD)
in 3 rounds
-
Latest Funding Round
$68.92 M (USD), Series C
Feb 24, 2025
-
Investors
Gree
& 16 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Readline
Readline offers a comprehensive portfolio of products and services, including Efficacy Care Raw Materials and Biomedicine Peptides.
Green production of bioactive raw materials for skincare is achieved to support health and beauty applications.
Scale production of peptide drugs using synthetic biology is accomplished to aid in the treatment of chronic diseases.
Funding Insights of Readline
Readline has successfully raised a total of $143.22M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $68.92 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $68.9M
-
First Round
First Round
(22 Nov 2021)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series C - Readline | Valuation |
investors |
|
| Dec, 2022 | Amount | Series B - Readline | Valuation | CoStone Capital | |
| Nov, 2021 | Amount | Series A - Readline | Valuation | Green Pine Capital Partners |
Investors in Readline
Readline has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Gree, Jinhong Holding Group and Oriental Fortune Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by Oriental Fortune Capital.
|
Founded Year | Domain | Location | |
|
Early- and growth-stage investments are directed toward hard technology sectors.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Readline
Financial Statements - Readline
Readline Comparisons
Competitors of Readline
Latest news on Readline
Frequently Asked Questions about Readline
Readline was founded in 2013 and raised its 1st funding round 8 years after it was founded.
Readline is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Readline is a funded company, having raised a total of $143.22M across 3 funding rounds to date. The company's 1st funding round was a Series A of $31.31M, raised on Nov 22, 2021.
Readline was founded in 2013 in Shenzhen, China, as an RD firm specializing in peptides. Manufacturing and exporting of peptides for cosmetic, pharmaceutical, and amino acid uses are conducted by the company. Operations occur within the biotechnology sector, with a focus on research, production, and international distribution. The firm is led by co-founder Jian Liu, serving global markets from its base in China.
Readline offers Efficacy Care Raw Materials and Biomedicine Peptides.
Readline has 17 investors. Key investors include Gree, Jinhong Holding Group, Oriental Fortune Capital, Green Pine Capital Partners, and Hunan caixin Investment Holding Group.